c-KIT inhibitors Early data suggest that mucosal or acral melanomas with activating pathogenic variants or amplifications in KIT may be sensitive to a variety of c-KIT inhibitors.[29-31] Phase II and phase III trials are available for patients with unresectable stage III or stage IV melanoma and a KIT pathogenic variant
Please consult with a healthcare professional before making any changes to your health regimen
A decomposition-fitting algorithm was used to subtract residual water signals
Ask for Certificates of Analysis to confirm that your medication has been tested for potency, sterility, and endotoxins
Su formato en tabletas permite una dosificacin cmoda y precisa
Caeque T, Baron L, Mller S, Carmona A, Colombeau L, Versini A, et al